A study conducted by Plisiecka-Hałasa et al. suggests that LOH in the TP53 loci 17p13, a dysfunctional mutation, confers cisplatin resistance in ovarian cancer patients [56]. The gene discussed is TP53; the disease is ovarian cancer.